Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

High-resolution cryo-EM analysis of the yeast ATP synthase in a lipid membrane.

Srivastava AP, Luo M, Zhou W, Symersky J, Bai D, Chambers MG, Faraldo-Gómez JD, Liao M, Mueller DM.

Science. 2018 May 11;360(6389). pii: eaas9699. doi: 10.1126/science.aas9699. Epub 2018 Apr 12.

PMID:
29650704
2.

A loop region of BAFF controls B cell survival and regulates recognition by different inhibitors.

Vigolo M, Chambers MG, Willen L, Chevalley D, Maskos K, Lammens A, Tardivel A, Das D, Kowalczyk-Quintas C, Schuepbach-Mallepell S, Smulski CR, Eslami M, Rolink A, Hummler E, Samy E, Fomekong Nanfack Y, Mackay F, Liao M, Hess H, Jiang X, Schneider P.

Nat Commun. 2018 Mar 23;9(1):1199. doi: 10.1038/s41467-018-03323-8.

3.

Best practices for managing large CryoEM facilities.

Alewijnse B, Ashton AW, Chambers MG, Chen S, Cheng A, Ebrahim M, Eng ET, Hagen WJH, Koster AJ, López CS, Lukoyanova N, Ortega J, Renault L, Reyntjens S, Rice WJ, Scapin G, Schrijver R, Siebert A, Stagg SM, Grum-Tokars V, Wright ER, Wu S, Yu Z, Zhou ZH, Carragher B, Potter CS.

J Struct Biol. 2017 Sep;199(3):225-236. doi: 10.1016/j.jsb.2017.07.011. Epub 2017 Aug 4.

4.

Cryo-EM structure of the protein-conducting ERAD channel Hrd1 in complex with Hrd3.

Schoebel S, Mi W, Stein A, Ovchinnikov S, Pavlovicz R, DiMaio F, Baker D, Chambers MG, Su H, Li D, Rapoport TA, Liao M.

Nature. 2017 Aug 17;548(7667):352-355. doi: 10.1038/nature23314. Epub 2017 Jul 6.

5.

A Highly Selective Hydantoin Inhibitor of Aggrecanase-1 and Aggrecanase-2 with a Low Projected Human Dose.

Durham TB, Marimuthu J, Toth JL, Liu C, Adams L, Mudra DR, Swearingen C, Lin C, Chambers MG, Thirunavukkarasu K, Wiley MR.

J Med Chem. 2017 Jul 13;60(13):5933-5939. doi: 10.1021/acs.jmedchem.7b00650. Epub 2017 Jun 29.

PMID:
28613895
6.

Analgesic and anti-inflammatory properties of novel, selective, and potent EP4 receptor antagonists.

Chandrasekhar S, Yu XP, Harvey AK, Oskins JL, Lin C, Wang X, Blanco MJ, Fisher MJ, Kuklish SL, Schiffler MA, Vetman T, Warshawsky AM, York JS, Bendele AM, Chambers MG.

Pharmacol Res Perspect. 2017 May 14;5(3):e00316. doi: 10.1002/prp2.316. eCollection 2017 Jun.

7.

The structural basis for the functional comparability of factor VIII and the long-acting variant recombinant factor VIII Fc fusion protein.

Leksa NC, Chiu PL, Bou-Assaf GM, Quan C, Liu Z, Goodman AB, Chambers MG, Tsutakawa SE, Hammel M, Peters RT, Walz T, Kulman JD.

J Thromb Haemost. 2017 Jun;15(6):1167-1179. doi: 10.1111/jth.13700. Epub 2017 May 3.

8.

Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design.

Jones SB, Pfeifer LA, Bleisch TJ, Beauchamp TJ, Durbin JD, Klimkowski VJ, Hughes NE, Rito CJ, Dao Y, Gruber JM, Bui H, Chambers MG, Chandrasekhar S, Lin C, McCann DJ, Mudra DR, Oskins JL, Swearingen CA, Thirunavukkarasu K, Norman BH.

ACS Med Chem Lett. 2016 Aug 2;7(9):857-61. doi: 10.1021/acsmedchemlett.6b00207. eCollection 2016 Sep 8.

9.

Lysophosphatidic acid provides a missing link between osteoarthritis and joint neuropathic pain.

McDougall JJ, Albacete S, Schuelert N, Mitchell PG, Lin C, Oskins JL, Bui HH, Chambers MG.

Osteoarthritis Cartilage. 2017 Jun;25(6):926-934. doi: 10.1016/j.joca.2016.08.016. Epub 2016 Sep 17.

10.

Identification and pharmacological characterization of a novel inhibitor of autotaxin in rodent models of joint pain.

Thirunavukkarasu K, Swearingen CA, Oskins JL, Lin C, Bui HH, Jones SB, Pfeifer LA, Norman BH, Mitchell PG, Chambers MG.

Osteoarthritis Cartilage. 2017 Jun;25(6):935-942. doi: 10.1016/j.joca.2016.09.006. Epub 2016 Sep 13.

11.

CATCHR, HOPS and CORVET tethering complexes share a similar architecture.

Chou HT, Dukovski D, Chambers MG, Reinisch KM, Walz T.

Nat Struct Mol Biol. 2016 Aug;23(8):761-3. doi: 10.1038/nsmb.3264. Epub 2016 Jul 18.

12.

Identification of potent and selective retinoic acid receptor gamma (RARγ) antagonists for the treatment of osteoarthritis pain using structure based drug design.

Hughes NE, Bleisch TJ, Jones SA, Richardson TI, Doti RA, Wang Y, Stout SL, Durst GL, Chambers MG, Oskins JL, Lin C, Adams LA, Page TJ, Barr RJ, Zink RW, Osborne H, Montrose-Rafizadeh C, Norman BH.

Bioorg Med Chem Lett. 2016 Jul 15;26(14):3274-3277. doi: 10.1016/j.bmcl.2016.05.056. Epub 2016 May 20.

PMID:
27261179
13.

Use of Osmotic Pumps to Establish the Pharmacokinetic-Pharmacodynamic Relationship and Define Desirable Human Performance Characteristics for Aggrecanase Inhibitors.

Wiley MR, Durham TB, Adams LA, Chambers MG, Lin C, Liu C, Marimuthu J, Mitchell PG, Mudra DR, Swearingen CA, Toth JL, Weller JM, Thirunavukkarasu K.

J Med Chem. 2016 Jun 23;59(12):5810-22. doi: 10.1021/acs.jmedchem.6b00398. Epub 2016 Jun 9.

PMID:
27194201
14.

Identification and Characterization of Novel Microsomal Prostaglandin E Synthase-1 Inhibitors for Analgesia.

Chandrasekhar S, Harvey AK, Yu XP, Chambers MG, Oskins JL, Lin C, Seng TW, Thibodeaux SJ, Norman BH, Hughes NE, Schiffler MA, Fisher MJ.

J Pharmacol Exp Ther. 2016 Mar;356(3):635-44. doi: 10.1124/jpet.115.228932. Epub 2016 Jan 6.

15.

Molecular Mechanism of V(D)J Recombination from Synaptic RAG1-RAG2 Complex Structures.

Ru H, Chambers MG, Fu TM, Tong AB, Liao M, Wu H.

Cell. 2015 Nov 19;163(5):1138-1152. doi: 10.1016/j.cell.2015.10.055. Epub 2015 Nov 5. Erratum in: Cell. 2015 Dec 17;163(7):1807.

16.

Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry.

Chiu PL, Bou-Assaf GM, Chhabra ES, Chambers MG, Peters RT, Kulman JD, Walz T.

Blood. 2015 Aug 20;126(8):935-8. doi: 10.1182/blood-2015-04-641688. Epub 2015 Jun 11.

17.

The SAR development of substituted purine derivatives as selective CB2 agonists for the treatment of chronic pain.

Guidetti R, Astles PC, Sanderson AJ, Hollinshead SP, Johnson MP, Chambers MG.

Bioorg Med Chem Lett. 2014 Dec 15;24(24):5572-5575. doi: 10.1016/j.bmcl.2014.11.006. Epub 2014 Nov 7.

PMID:
25466177
18.

Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.

Durham TB, Klimkowski VJ, Rito CJ, Marimuthu J, Toth JL, Liu C, Durbin JD, Stout SL, Adams L, Swearingen C, Lin C, Chambers MG, Thirunavukkarasu K, Wiley MR.

J Med Chem. 2014 Dec 26;57(24):10476-85. doi: 10.1021/jm501522n. Epub 2014 Dec 5.

PMID:
25415648
19.

Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain.

Benschop RJ, Collins EC, Darling RJ, Allan BW, Leung D, Conner EM, Nelson J, Gaynor B, Xu J, Wang XF, Lynch RA, Li B, McCarty D, Nisenbaum ES, Oskins JL, Lin C, Johnson KW, Chambers MG.

Osteoarthritis Cartilage. 2014 Apr;22(4):578-85. doi: 10.1016/j.joca.2014.01.009. Epub 2014 Feb 6. Erratum in: Osteoarthritis Cartilage. 2014 Nov;22(11):1951. Nisenbaum, E S [added].

20.

Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain.

Hollinshead SP, Tidwell MW, Palmer J, Guidetti R, Sanderson A, Johnson MP, Chambers MG, Oskins J, Stratford R, Astles PC.

J Med Chem. 2013 Jul 25;56(14):5722-33. doi: 10.1021/jm400305d. Epub 2013 Jul 3.

PMID:
23795771
21.

Structural analysis of the oligomeric states of Helicobacter pylori VacA toxin.

Chambers MG, Pyburn TM, González-Rivera C, Collier SE, Eli I, Yip CK, Takizawa Y, Lacy DB, Cover TL, Ohi MD.

J Mol Biol. 2013 Feb 8;425(3):524-35. doi: 10.1016/j.jmb.2012.11.020. Epub 2012 Nov 20.

22.

Discovery and optimization of novel purines as potent and selective CB2 agonists.

Hollinshead SP, Astles PC, Chambers MG, Johnson MP, Palmer J, Tidwell MW.

Bioorg Med Chem Lett. 2012 Aug 1;22(15):4962-6. doi: 10.1016/j.bmcl.2012.06.035. Epub 2012 Jun 16.

PMID:
22765893
23.

Predicting EQ-5D values using the SGRQ.

Starkie HJ, Briggs AH, Chambers MG, Jones P.

Value Health. 2011 Mar-Apr;14(2):354-60. doi: 10.1016/j.jval.2010.09.011.

24.

Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis.

Schuelert N, Johnson MP, Oskins JL, Jassal K, Chambers MG, McDougall JJ.

Pain. 2011 May;152(5):975-81. doi: 10.1016/j.pain.2010.11.025. Epub 2010 Dec 24.

PMID:
21185649
25.

The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the mouse.

Glasson SS, Chambers MG, Van Den Berg WB, Little CB.

Osteoarthritis Cartilage. 2010 Oct;18 Suppl 3:S17-23. doi: 10.1016/j.joca.2010.05.025.

26.

A short-term pharmacodynamic model for monitoring aggrecanase activity: injection of monosodium iodoacetate (MIA) in rats and assessment of aggrecan neoepitope release in synovial fluid using novel ELISAs.

Swearingen CA, Chambers MG, Lin C, Marimuthu J, Rito CJ, Carter QL, Dotzlaf J, Liu C, Chandrasekhar S, Duffin KL, Mitchell PG, Durham TB, Wiley MR, Thirunavukkarasu K.

Osteoarthritis Cartilage. 2010 Sep;18(9):1159-66. doi: 10.1016/j.joca.2010.02.019. Epub 2010 Jul 13.

27.

Structural organization of the functional domains of Clostridium difficile toxins A and B.

Pruitt RN, Chambers MG, Ng KK, Ohi MD, Lacy DB.

Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13467-72. doi: 10.1073/pnas.1002199107. Epub 2010 Jul 12.

28.

Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV.

Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG.

Pharmacoeconomics. 2010;28(11):1025-39. doi: 10.2165/11535540-000000000-00000.

PMID:
20575592
29.

Reconstitution of Helicobacter pylori VacA toxin from purified components.

González-Rivera C, Gangwer KA, McClain MS, Eli IM, Chambers MG, Ohi MD, Lacy DB, Cover TL.

Biochemistry. 2010 Jul 13;49(27):5743-52. doi: 10.1021/bi100618g.

30.

Analysis of early changes in the articular cartilage transcriptisome in the rat meniscal tear model of osteoarthritis: pathway comparisons with the rat anterior cruciate transection model and with human osteoarthritic cartilage.

Wei T, Kulkarni NH, Zeng QQ, Helvering LM, Lin X, Lawrence F, Hale L, Chambers MG, Lin C, Harvey A, Ma YL, Cain RL, Oskins J, Carozza MA, Edmondson DD, Hu T, Miles RR, Ryan TP, Onyia JE, Mitchell PG.

Osteoarthritis Cartilage. 2010 Jul;18(7):992-1000. doi: 10.1016/j.joca.2010.04.012. Epub 2010 Apr 29.

31.

Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.

Earnshaw SR, Wilson MR, Dalal AA, Chambers MG, Jhingran P, Stanford R, Mapel DW.

Respir Med. 2009 Jan;103(1):12-21. doi: 10.1016/j.rmed.2008.10.005. Epub 2008 Nov 17.

32.

The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.

Sollano JA, Kirsch JM, Bala MV, Chambers MG, Harpole LH.

Clin Pharmacol Ther. 2008 Aug;84(2):263-6. doi: 10.1038/clpt.2008.117. Epub 2008 Jun 11.

PMID:
18547999
33.

Pharmacoeconomics in COPD: lessons for the future.

Starkie HJ, Briggs AH, Chambers MG.

Int J Chron Obstruct Pulmon Dis. 2008;3(1):71-88. Review.

34.

The role of adenosine in chondrocyte death in murine osteoarthritis and in a murine chondrocyte cell line.

Mistry D, Chambers MG, Mason RM.

Osteoarthritis Cartilage. 2006 May;14(5):486-95. Epub 2006 Jan 27.

35.

The influence of context on role behaviors of perioperative nurses.

McGarvey HE, Chambers MG, Boore JR.

AORN J. 2004 Dec;80(6):1103-14, 1117-20.

PMID:
15641664
36.

Chondrocyte death during murine osteoarthritis.

Mistry D, Oue Y, Chambers MG, Kayser MV, Mason RM.

Osteoarthritis Cartilage. 2004 Feb;12(2):131-41.

37.

Distribution of Endo180 receptor and ligand in developing articular cartilage.

Howard MJ, Chambers MG, Mason RM, Isacke CM.

Osteoarthritis Cartilage. 2004 Jan;12(1):74-82.

39.

Multimedia software to help caregivers cope.

Chambers MG, Connor SL, McGonigle M, Diver MG.

J Am Med Inform Assoc. 2003 Sep-Oct;10(5):504-11. Epub 2003 Jun 4.

40.

The economic burden of heart failure and implantable cardioverter defibrillators: The value of noninvasive imaging of high-risk patients.

Chambers MG, Narula J, Cerqueira MD.

J Nucl Cardiol. 2002 Sep-Oct;9(5 Suppl):71S-80S. No abstract available.

PMID:
12271267
41.

Metalloproteinase and tissue inhibitor of metalloproteinase expression in the murine STR/ort model of osteoarthritis.

Flannelly J, Chambers MG, Dudhia J, Hembry RM, Murphy G, Mason RM, Bayliss MT.

Osteoarthritis Cartilage. 2002 Sep;10(9):722-33.

42.

Development of a decision-analytic model of stroke care in the United States and Europe.

Chambers MG, Koch P, Hutton J.

Value Health. 2002 Mar-Apr;5(2):82-97.

43.
44.

Exploratory study of nursing in an operating department: preliminary findings on the role of the nurse.

McGarvey HE, Chambers MG, Boore JR.

Intensive Crit Care Nurs. 1999 Dec;15(6):346-56.

PMID:
11868582
45.

Expression of collagen and aggrecan genes in normal and osteoarthritic murine knee joints.

Chambers MG, Kuffner T, Cowan SK, Cheah KS, Mason RM.

Osteoarthritis Cartilage. 2002 Jan;10(1):51-61.

46.
47.

Clinical and economic evaluation of surgical treatments for faecal incontinence.

Malouf AJ, Chambers MG, Kamm MA.

Br J Surg. 2001 Aug;88(8):1029-36. Review.

PMID:
11488786
48.
49.

The STR/ort mouse and its use as a model of osteoarthritis.

Mason RM, Chambers MG, Flannelly J, Gaffen JD, Dudhia J, Bayliss MT.

Osteoarthritis Cartilage. 2001 Feb;9(2):85-91. Review. No abstract available.

50.

Development and definition of the role of the operating department nurse: a review.

McGarvey HE, Chambers MG, Boore JR.

J Adv Nurs. 2000 Nov;32(5):1092-100. Review.

PMID:
11114993

Supplemental Content

Loading ...
Support Center